Mexico City, Mexico – On January 18, Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®"), the third-generation drug-eluting stent ("DES") in-house developed by Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®"), received the regulatory approval from the health authority of the Mexican government - the Federal Commission for the Protection against Sanitary Risk (in Spanish, Comisión Federal para la Protección contra Riesgos Sanitarios, COFEPRIS). It is another registration certificate Firehawk® received in the South America markets following those in Peru, Brazil and Argentina.
As the world's lowest drug dosage stent, Firehawk® combines the merits of the bare metal stent and DES. It adopts unique in-groove abluminal coating design and target-eluting technique, which allow Firehawk® to achieve the same clinical efficacy with significantly low drug loading, benefiting vascular early healing.
Before Firehawk®'s regulatory approval in Mexico, another product of MicroPort® - FOXTROT™ PRO Balloon Dilation Catheter had gained the registration certificate from the COFEPRIS. With them, MicroPort® will provide better and more comprehensive medical solutions for South American patients by offering stent and balloon products used in PCI in the Mexico market, which will also lay a solid foundation for the company to further expand the local market.
This website may store cookies on your browser. Cookies are mostly used to make the website work as you expect it to. No cookie will directly identify you, but it can give you a more personalized browsing experience.
MicroPort respects your privacy rights, so you can block some types of cookies. Technically non-essential cookies and tracking mechanisms, that enable us to provide you with customized offers (marketing cookies), are only used if you have given prior consent to such use.
By clicking “Save”, only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings.